Navigation Links
Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
Date:10/31/2007

006.

Income tax expense totaled euro 2,108 million, versus euro 2,282 million in the nine months to end September 2006. The reported tax rate was 28.1%, compared with 29.5% in the nine months to end September 2006. The 2007 figure includes a net gain of euro 244 million relating to movements in provisions and tax risks/settlements of tax disputes, and a deferred tax expense of euro 51m related to cuts in tax rates in Germany, Spain and the United Kingdom. The 2006 figure was influenced by the low income tax charge arising on the Exubera(R) gain. The effective tax rate for the first nine months of 2007 was 30.7%.

The share of profits of associates was euro 582 million, against euro 509 million in the nine months to end September 2006. The share of after-tax profits from territories managed by BMS under the Plavix(R) and Avapro(R) alliance was euro 376 million, versus euro 308 million in the nine months to end September 2006. There was a decrease in the contribution from Sanofi- Pasteur MSD, currently in the Gardasil(R) launch phase, while there was an increase in the contribution from Merial.

Minority interests were euro 322 million, versus euro 290 million in the nine months to end September 2006. This line includes the share of pre-tax profits paid to BMS from territories managed by sanofi-aventis (euro 307 million, versus euro 277 million in the nine months to end September 2006).

Adjusted net income fell by 0.3% to euro 5,648 million, while adjusted earnings per share (adjusted EPS) was euro 4.18 (0.7% down on the 2006 9-month figure of euro 4.21), based on an average number of shares outstanding of 1,350.8 million in the nine months to end September 2007 and 1,346.1 million in the nine months to end September 2006.

Excluding selected items (see Appendix 5), adjusted net income was euro 5,532 million (6.3% up on the 20069-month figure of euro 5,203 million); and adjusted EPS was euro 4.10 (5.9% up on the 2006 9-month figure of euro 3
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Sanofi-Aventis Allows Thais To Make Plavix
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... estrogen therapy does not decrease, but may increase, the ... studies have reported an association between postmenopausal estrogen use ... of estrogen or estrogen plus progestin in women aged ... dementia. In the estrogen-only trial, researchers found 47 participants ...
... the body. Parkinson's patients are particularly at risk for ... a drug commonly used to treat the disease, produces ... patients with Parkinson’s disease who have high levels of ... worse cognitive functioning than other patients who have normal ...
... about 40 milligrams of vitamin C daily as new ... may protect against rheumatoid arthritis. ,Researchers studied 23,000 ... 74. Participants' diets were assessed by using seven-day-food-intake diaries.It ... or more joints for at least one month and ...
... symptoms of rheumatoid arthritis as well as keep cardiovascular ... have an anti-inflammatory effect and are well-known for reducing ... puts sufferers at an increased risk of cardiovascular disease. ... day of atorvastatin or a placebo in addition to ...
... testicles and cause prostate cancer cells to grow. Lowering ... grow more slowly. However, hormone therapy will not cure ... such as surgery or radiation are not good options. ... cancer significantly increases the risk of fractures.For the study ...
... be risking bone loss say researchers. Investigators tested post-menopausal women ... likely to have lower scores on heel and hip tests ... ,More than 6,000 women participated in the study.The loss ... both the heel bone and the hip. Those numbers held ...
Cached Medicine News:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Verinata Health, Inc., a privately-held company dedicated to maternal ... corporate headquarters and laboratory operations to 800 Saginaw Drive, ... a much larger and state-of-the art facility is a ... growth and expansion expected with the launch of our ...
... PITTSBURGH, Dec. 7, 2011 HealthpointCapital, LLC ("HealthpointCapital") ... Inc. ("Blue Belt" or "Company"). Blue Belt is ... for use initially in orthopedic procedures and then ... ("ENT"). Terms of the transaction were not disclosed. ...
Cached Medicine Technology:Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations 2HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO 2
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
... been shown to produce the highest contact ... fixed bearing component. This combination of high ... loading minimizes the risk of polyethylene deterioration ... symmetrical component design streamlines inventory requirements without ...
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
The AGC dual articular knee is indicated for severe primary or revision cases and features a patented unique articulation which allows controlled rotation of the femoral component about a central piv...
Medicine Products: